5013 completed. 5013 Phase 2, 818 Phase 1, 475 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5013 | Completed 5013 |
| Phase 1 | 818 | Completed 818 |
| Phase 3 | 475 | Completed 475 |
Follow Infections: new trials by email Literature Review of Infections trials Research Report on Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chemical vs Mechanical Pleural Adhesiolysis for Liberation of Captive Pleura in Stacked Effusion Intrapleural Hydrogen Peroxide (H_2O_2), Intrapleural Corticosteroids, Thoracoscopic Mechanical Pleurolysis - Pleural Infection, Pleural Adhesions | Phase 2 | Completed | Delta University for Science and Technology | 36 | 2026-03-26 | 2026-07-20 |
| Environmental Exposure Unit Trial in Subjects With Ragweed-induced Allergic Rhinitis INI-2004, Placebo - Allergic Rhinitis Due to Allergens, Rhinitis Allergic | Phase 2 | Completed | Inimmune Corporation | 78 | 2026-01-19 | 2026-04-29 |
| Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B1) KAE609 (Cipargamin), SoC (Coartem), INE963 - Uncomplicated Plasmodium Falciparum Malaria | Phase 2 | Completed | Novartis Pharmaceuticals | 95 | 2025-10-10 | 2026-09-10 |
| A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above Flu mRNA (Formulation B1), Flu mRNA (Formulation B3), Flu mRNA(Formulation A) - Influenza, Human | Phase 2 | Completed | GlaxoSmithKline | 971 | 2025-10-07 | 2026-09-18 |
| A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa Topical roflumilast 0.3% foam - Hidradenitis Suppurativa | Phase 2 | Completed | Tulane University | 10 | 2025-09-25 | 2026-10-09 |
| PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine (RZ700), 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (Prevnar 13) - Pneumococcal Infectious Disease | Phase 2 | Completed | Reinovax Biologics Co., LTD | 480 | 2025-09-11 | 2026-07-27 |
| Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μg OVX836 480µg, Saline Solution - Influenza | Phase 2 | Completed | Osivax | 2891 | 2025-09-08 | 2026-10-16 |
| N-Acetylcysteine in Patients With Leptospirosis N-acetylcysteine, Placebo - Leptospirosis | Phase 2 | Completed | Dr Cipto Mangunkusumo General Hospital | 64 | 2025-08-30 | 2026-09-16 |
| A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older Flu mRNA (Formulation A), Flu mRNA (Formulation B), Comparator 1 - Influenza, Human | Phase 2 | Completed | GlaxoSmithKline | 776 | 2025-08-25 | 2026-05-28 |
| Effects of Lumbrokinase DLBS1033 on D-Dimer, Interleukin-6, and Clinical Outcomes in Patients With Pneumonia and Sepsis Placebo Tablet(s), DLBS1033 - Pneumonia, Sepsis | Phase 2 | Completed | Universitas Sebelas Maret | 50 | 2025-08-14 | 2026-10-23 |
| L9LS in Women of Childbearing Potential in Mali Single dose of 1800 mg L9LS SC, Placebo - Malaria | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 279 | 2025-07-22 | 2026-06-10 |
| Clinical Trial of PCV24 in Adults Aged ≥18 Years Sinovac Low-dosage PCV24, Sinovac Middle-dosage PCV24, Sinovac High-dosage PCV24 - Pneumococcal Infectious Disease | Phase 1 / Phase 2 | Completed | Sinovac Life Sciences Co., Ltd. | 385 | 2025-06-18 | 2026-04-21 |
| A Study of S-892216 in Participants With COVID-19 S-892216, Placebo - COVID-19 | Phase 2 | Completed | Shionogi | 282 | 2025-06-06 | 2026-09-21 |
| Evaluating the Neuromodulatory Effect of Ketamine in Long COVID-19 Ketamine only - Long COVID | Phase 2 | Completed | University of Texas at Austin | 20 | 2025-06-05 | 2026-09-17 |
| Probiotic Use for Recovery Enhancement From Long COVID-19 Probiotic Agent, Placebo - Post-Acute COVID-19 Syndrome | Phase 2 | Completed | Rush University Medical Center | 194 | 2025-05-13 | 2026-08-07 |
| iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine Radiopharmaceutical: gallium-68-deferoxamine ([68Ga]Ga-DFO-B) - Pulmonary Aspergillosis, Chronic Pulmonary Aspergillosis | Phase 2 | Completed | Radboud University Medical Center | 10 | 2025-05-01 | 2026-08-18 |
| NE3107 in Adults With Neurological Symptoms of Long COVID NE3107, Placebo - Long COVID | Phase 2 | Completed | BioVie Inc. | 203 | 2025-04-29 | 2026-09-22 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult Participants SNA02-48, Placebo, HTIG - Tetanus | Phase 1 / Phase 2 | Completed | Sinovac Life Sciences Co., Ltd. | 255 | 2025-04-28 | 2026-06-03 |
| To Evaluate the Efficacy and Safety of ALC-2203 in Patients With Acute Bronchitis ALC-2203-1, ALC-2203-2, ALC-2203-AC - Acute Bronchitis | Phase 2 | Completed | Korea Arlico Pharm. Co., Ltd | 169 | 2025-04-23 | 2025-12-24 |
| Efficacy and Safety of Oxantel Pamoate in Children Infected With Trichuris Trichiura Oxantel Pamoate, Mebendazole - Trichuris Trichiura; Infection, Hookworm Infection | Phase 2 | Completed | Jennifer Keiser | 163 | 2025-04-16 | 2025-06-08 |
Showing 20 of 5013. Sign in to see all of them.
HIV Infections (737) · COVID-19 (638) · Influenza, Human (413) · Acquired Immunodeficiency Syndrome (298) · Hepatitis C (267) · Burkitt Lymphoma (213) · Hepatitis C, Chronic (194) · Lymphoma, Large B-Cell, Diffuse (156) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (153) · Lymphoma, Follicular (152) · Lymphoma, Non-Hodgkin (145) · Malaria (142) · Coronavirus Infections (141) · Lymphoma (139)
Virus Diseases (3205) · RNA Virus Infections (2606) · Respiratory Tract Diseases (1491) · Communicable Diseases (1472) · Blood-Borne Infections (1394) · Respiratory Tract Infections (1378) · Immune System Diseases (1210) · Pathological Conditions, Signs and Symptoms (1165) · Urogenital Diseases (1109) · Pathologic Processes (1041) · Genital Diseases (1015) · Lung Diseases (956) · Sexually Transmitted Diseases, Viral (924) · Sexually Transmitted Diseases (914)
Ribavirin (205) · peginterferon alfa-2a (118) · Ritonavir (102) · Cyclophosphamide (87) · Influenza Vaccines (85) · Saline Solution (79) · Sodium Chloride (79) · Zidovudine (77) · Tenofovir (69) · Lamivudine (61) · Standard of Care (57) · Etoposide (52) · Sofosbuvir (49) · Rituximab (47) · Filgrastim (45)
National Institute of Allergy and Infectious Diseases (NIAID) (420) · GlaxoSmithKline (257) · Gilead Sciences (92) · Merck Sharp & Dohme LLC (91) · Sanofi Pasteur, a Sanofi Company (91) · Pfizer (61) · National Cancer Institute (NCI) (54) · Novartis Vaccines (52) · University of Oxford (47) · U.S. Army Medical Research and Development Command (45) · Bristol-Myers Squibb (38) · Fred Hutchinson Cancer Center (36) · Hoffmann-La Roche (36) · Centers for Disease Control and Prevention (34) · London School of Hygiene and Tropical Medicine (28)
United States (2338) · Canada (345) · Germany (309) · United Kingdom (300) · France (297) · Spain (267) · South Africa (248) · Puerto Rico (203) · Belgium (193) · Australia (186) · Italy (185) · China (172) · Brazil (151) · Thailand (133) · Poland (129)
PMID 34473343, PMID 35713300, PMID 34013969, PMID 36734509, PMID 37162745, PMID 40190112, PMID 41276263, PMID 32499241, PMID 34658014, PMID 34895272, PMID 35257644, PMID 39377226, PMID 39756216, PMID 40099800, PMID 25424918, PMID 28193518, PMID 28495354, PMID 30012435, PMID 30664876, PMID 30923816, PMID 30977945, PMID 32251768, PMID 33020485, PMID 33305842, PMID 33502773, PMID 33542052, PMID 33754144, PMID 34817414, PMID 35164991, PMID 35244208, PMID 36875126, PMID 37068952, PMID 37781954, PMID 37947276, PMID 38077399, PMID 39230271, PMID 40342086, PMID 40592258, PMID 40655875, PMID 41720282, PMID 17242396, PMID 17287313, PMID 18832244, PMID 18832245, PMID 19118378, PMID 19150418, PMID 19191652, PMID 20018365, PMID 2022660, PMID 20657177
2014 (43), 2009 (33), 2015 (27), 2008 (26), 2016 (26), 2017 (22), 2019 (18), 2018 (14), 2023 (14), P30CA015704 (11), 2005 (9), 2004 (8), U10CA032102 (8), P30CA043703 (7), P30CA008748 (6)